Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 4, 2003, Pages 282-291

  Cho, Daniel ^a   Di Blasio, Christopher J ^a   Rhee, Audrey C ^a   Kattan, Michael W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Androgen deprivation; Hormone refractory; Nomograms; Prediction; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; ANTIANDROGEN; BICALUTAMIDE; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EFLORNITHINE; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; GEMCITABINE; GONADORELIN AGONIST; HEMOGLOBIN; HYDROCORTISONE; LACTATE DEHYDROGENASE; MEGESTROL; MITOGUAZONE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; STRONTIUM; SURAMIN; VINBLASTINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER; TUMOR PROTEIN;

ANDROGEN DEPRIVATION THERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CONFERENCE PAPER; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; MEDICAL DECISION MAKING; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; DISEASE COURSE; DRUG RESISTANCE; MALE; MORTALITY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM PROTEINS; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 2142652101     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(03)00057-7     Document Type: Conference Paper

References (55)

1. Walsh P.C., DeWeese T.L., Eisenberger M.A. A structured debate immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol. 166:2001;508-515
2. Joseph I.B., Nelson J.B., Denmeade S.R., et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 3:1997;2507-2511
3. Eisenberger M.A., Nelson W.G. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution. J Natl Cancer Inst. 88:1996;779-781
4. Scher H.I., Kelly W.M., Zhang Z.F., et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 91:1999;244-251
5. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer results of the cancer and leukemia group B 9182 study. J Clin Oncol. 17:1999;2506-2513
6. Small E.J., Halabi S., Ratain M.J., et al. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 20:2002;3369-3375
7. Urakami S., Igawa M., Kikuno N., et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol. 168:2002;2444-2450
8. Clark J.A., Wray N.P., Ashton C.M. Living with treatment decisions regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol. 19:2001;72-80
9. Tso C.L., McBride W.H., Sun J., et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 6:2000;220-233
10. Smaletz O., Scher H.I., Small E.J., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 20:2002;3972-3982
11. Petrylak D.P., Scher H.I., Li Z., et al. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer. 70:1992;2870-2878
12. Dawson N.A., Conaway M., Halabi S., et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma cancer and leukemia group B study 9181. Cancer. 88:2000;825-834
13. Kantoff P.W., Halabi S., Farmer D.A., et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol. 19:2001;3025-3028
14. Bok R.A., Halabi S., Fei D.T., et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients a cancer and leukemia group B study. Cancer Res. 61:2001;2533-2536
15. Dowling A.J., Panzarella T., Ernst D.S., et al. A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. Ann Oncol. 12:2001;773-778
16. Morioka M., Kobayashi T., Furukawa Y., et al. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int. 68:2002;10-15
17. Halabi S., Small E.J., Kantoff P., et al. A Prognostic Model for Predicting Overall Survival in Men with Hormone Refractory Metastatic Prostate Cancer. J Clin Onc. 21:2003;1232-1237
18. Berry W.R., Laszlo J., Cox E., et al. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer. 44:1979;763-775
19. Emrich L.J., Priore R.L., Murphy G.P., et al. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res. 45:1985;5173-5179
20. Sridhara R., Eisenberger M.A., Sinibaldi V.J., et al. Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin. Cancer Epidemiol Biomarkers Prev. 7:1998;631-634
21. DeWys W.D., Begg C.B., Brodovsky H., et al. A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer prognostic factors and response. Prostate. 4:1983;1-11
22. Soloway M.S., Ishikawa S., van der Zwaag R., et al. Prognostic factors in patients with advanced prostate cancer. Urology. 33:1989;53-56
23. Kelly W.K., Scher H.I., Mazumdar M., et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 11:1993;607-615
24. Smith D.C., Dunn R.L., Strawderman M.S., et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 16:1998;1835-1843
25. George D.J., Halabi S., Shepard T.F., et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 7:2001;1932-1936
26. Halabi S., Small E.J., Hayes D.F., et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer a nested study within CALGB 9583. J Clin Oncol. 21:2003;490-495
27. Kleinbaum D.G. Survival analysis a self-learning text. 1996;30-33 Springer-Verlag, New York
28. Kattan M.W., Zelefsky M.J., Kupelian P.A., et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 18:2000;3352-3359
29. Kattan M.W., Leung D.H., Brennan M.F. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 20:2002;791-796
30. Ross P.L., Gerigk C., Gonen M., et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol. 20:2002;82-88
31. Kattan M.W., Scardino P.T. Prediction of Progression Nomograms of Clinical Utility. Clin Prostate Cancer. 1:2002;90-96
32. Ross P.L., Scardino P.T., Kattan M.W. A catalog of prostate cancer nomograms. J Urol. 165:2001;1562-1568
33. Kattan M.W., Eastham J.A., et al. Algorithms for PSA recurrence after treatment of localized prostate cancer. Clinical Prostate Cancer. 1:2003;221-226
34. Shortliffe E.H. Computer programs to support clinical decision making. JAMA. 258:1987;61-66
35. Shortliffe E.H. Medical expert systems-knowledge tools for physicians. W J Med. 145:1986;830-839
36. Meehl P., et al. Clinical versus statistical prediction A theoretical analysis and review of the evidence. 1954;University of Minnesota Press, Minneapolis
37. Johnston M.E., Langston K.B., Haynes R.B. Effects of computer-based clinical decision support systems on clinician performance and patient outcome A critical appraisal of research. Ann Intern Med. 120:1994;135-142
38. Graefen M., Karakiewicz P.I., Cagiannos I., et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 20:2002;3206-3212
39. Kattan M.W. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients preoperative application in prostate cancer. Curr Opin Urol. 13:2003;111-116
40. Mazumdar M., Fazzari M., Panageas K.S. A standardization method to adjust for the effect of patient selection in phase II clinical trials. Stat Med. 20:2001;883-892
41. Harrell F.E. Jr, Lee K.L., Mark D.B. Multivariable prognostic models Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 15:1996;361-387
42. Burke H.B., Goodman P.H., Rosen D.B. Artificial Neural Networks Improve the Accuracy of Cancer Survival Prediction. Cancer. 79:1997;857-862
43. Stamey T.A., Yemoto C.M., McNeal J.E. Prostate cancer is highly predictable A prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol. 163:2000;1155-1160
44. Calvanese C.B., Kahane H., Carlson G.D. A presurgical staging of prostate cancer. Infections in Urology. 1999;22-28
45. Bauer J.J., Connelly R.R., Seterhenn I.A., et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol. 159:1998;929-933
46. Harrell F.E. Jr, Margolis P.A., Gove S. Development of a clinical prediction model for an ordinary outcome the World Health Organization multicenter study of clinical signs and etiological agents of pneumonia, sepsis, and meningitis in young infants. WHO/ARI young infant multicenter study group. Stat Med. 17:1998;909-944
47. Snow P.B., Smith D.S., Catalona W.J. Artificial neural networks in the diagnosis and prognosis of prostate cancer a pilot study. J Urol. 152:1994;1923-1926
48. Begg C.B., Cramer I.D., Venkatraman F.S. Comparing tumour staging and grading systems A case study and a review of the issues, using thymoma as a model. Stat Med. 19:2000;1997-2014
49. Efron B., Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. American Statistics. 37:1983;36-48
50. Harrell F.E. Jr, Lee K.L., Califf R.M., et al. Regression modelling strategies for improved prognostic prediction. Stat Med. 3:1984;143-152
51. Small E.J., Meyer M., Marshall M.E. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer results of a randomized Phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. JCO. 18:2000;1440-1450
52. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 90:1998;766-771
53. Kattan M.W., Potters L., Blasko J.C., et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 58:2001;393-399
54. Graefen M., Karakiewicz P.I., Cagiannos I., et al. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol. 7:2002;141
55. Thompson I.M., Tangen C., Basler J., et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 168:2002;1008-1012